Trial Profile
A Phase II, Double-Blind, Randomized, Multi-Center, Adaptive Dose-Ranging, Placebo-Controlled, Parallel-Group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-Remitting Multiple Sclerosis. [FOR EXTENSION STUDY SEE 7000230025]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms BOLD
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Oct 2012 Results assessing the correlation between magnetic resonance imaging and lymphocyte counts presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 13 Oct 2012 Primary analysis presented at the28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.